Janet Hopkins

Directeur Technique/Scientifique/R&D chez AURA BIOSCIENCES, INC.

Fortune : 1 M $ au 30/04/2024

59 ans

Health Technology

Consumer Services

Postes actifs de Janet Hopkins

Sociétés	Poste	Début	Fin
GYROSCOPE THERAPEUTICS HOLDINGS PLC	Directeur/Membre du Conseil	17/02/2022	-
AURA BIOSCIENCES, INC.	Directeur Technique/Scientifique/R&D	16/10/2023	-

Sociétés	Poste	Début	Fin
NOVARTIS AG	Corporate Officer/Principal	01/11/2021	01/10/2023
Gyroscope Therapeutics Ltd. Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.	Directeur Général	01/12/2021	01/10/2023

McMaster University

Doctorate Degree

Internationale

Opérationnelle

Director/Board Member	1
Chief Tech/Sci/R&D Officer	1
Corporate Officer/Principal	1

Sectorielle

Health Technology	5
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
AURA BIOSCIENCES, INC.	Health Technology
NOVARTIS AG	Health Technology

Entreprise privées	2
Gyroscope Therapeutics Holdings Plc Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom.	Health Technology
Gyroscope Therapeutics Ltd. Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.	Health Technology